GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Turn Therapeutics TTRX · USD

N/A · US listing · 🇺🇸 United States

Compare

9.79

+3.27%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Turn Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Turn Therapeutics is based in Westlake Village, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TTRX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $3.2m. At that date it held total assets of $12.2m and shareholders' equity of $4.7m.

Read the filing on SEC.gov ↗

Company facts

Sector
N/A
Industry
N/A
Listed since
8 Oct 2025
Head office
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE, CA, 91362
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Bradley BurnamChief Executive Officer, Director, since 2018$429,320
  • Mr. Zuraiz ChaudharyInterim Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
  • Dr. Neilesh GhodadraChief Medical Officer, Director, since 2018
  • Mr. Martin DewhurstIndependent Director
  • Mr. Andrew GengosIndependent Director
  • Mr. Arthur GoldenIndependent Director Nominee
  • Dr. Kent KesterIndependent Director Nominee

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • PermaFusion enables stable suspension of polar APIs in oil-based carriers without emulsifiers.
  • Patented mixing process supports development of dermatological disease treatments like eczema.
  • Primary programs include GX-03/Hexagen for wounds, burns, and moderate to severe eczema.

Weaknesses

  • Company went public on 8 October 2025, indicating a very recent market entry.
  • Headquarters located in Westlake Village, California, may limit local operational diversity.
  • Focus remains strictly on dermatological diseases, potentially restricting broader therapeutic market reach.

Opportunities

  • GX-03/Hexagen for Wounds offers medical device solutions for treating burns effectively.
  • AtopX represents a medical device opportunity for managing dermatitis conditions broadly.
  • Sterile Gauze Impregnated with GX-03/Hexagen provides new product lines for wound care.

Threats

  • Reliance on patented PermaFusion process creates vulnerability if intellectual property protection fails.
  • Moderate to severe eczema market may face intense competition from established therapies.
  • Operational research focus might delay commercialization of Hexagen and AtopX products significantly.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.